These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 37502330)

  • 1. Engineered vitamin E-tethered non-immunogenic facial lipopeptide for developing improved siRNA based combination therapy against metastatic breast cancer.
    Mallick AM; Biswas A; Mishra S; Jadhav S; Chakraborty K; Tripathi A; Mukherjee A; Roy RS
    Chem Sci; 2023 Jul; 14(29):7842-7866. PubMed ID: 37502330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Nanostructured Facial Lipopeptide as Highly Efficient Molecular Transporter.
    Dutta C; Chakraborty K; Sinha Roy R
    ACS Appl Mater Interfaces; 2015 Aug; 7(33):18397-405. PubMed ID: 26238518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered Histidine-Enriched Facial Lipopeptides for Enhanced Intracellular Delivery of Functional siRNA to Triple Negative Breast Cancer Cells.
    Biswas A; Chakraborty K; Dutta C; Mukherjee S; Gayen P; Jan S; Mallick AM; Bhattacharyya D; Sinha Roy R
    ACS Appl Mater Interfaces; 2019 Feb; 11(5):4719-4736. PubMed ID: 30628773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing Peptide-Functionalized Multivalent Gold Nanorods for Promoting Enhanced Gene Silencing and Managing Breast Cancer Metastasis.
    Chakraborty K; Biswas A; Mishra S; Mallick AM; Tripathi A; Jan S; Sinha Roy R
    ACS Appl Bio Mater; 2023 Feb; 6(2):458-472. PubMed ID: 36651932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
    Yang Z; Liu T; Xie Y; Sun Z; Liu H; Lin J; Liu C; Mao ZW; Nie S
    Acta Biomater; 2015 Oct; 25():194-204. PubMed ID: 26193000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
    Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
    Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system.
    Zhang W; Meng J; Ji Y; Li X; Kong H; Wu X; Xu H
    Nanoscale; 2011 Sep; 3(9):3923-32. PubMed ID: 21845256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
    Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
    Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
    J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioreducible, arginine-rich polydisulfide-based siRNA nanocomplexes with excellent tumor penetration for efficient gene silencing.
    Zhang X; Hong K; Sun Q; Zhu Y; Du J
    Biomater Sci; 2021 Jul; 9(15):5275-5292. PubMed ID: 34180478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
    Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
    Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles.
    Lokras A; Thakur A; Wadhwa A; Thanki K; Franzyk H; Foged C
    Front Bioeng Biotechnol; 2020; 8():601155. PubMed ID: 33520957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer.
    Gote V; Pal D
    Bioengineering (Basel); 2021 Apr; 8(4):. PubMed ID: 33916786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. siRNA and targeted delivery systems in breast cancer therapy.
    Mirzaei S; Paskeh MDA; Entezari M; Bidooki SH; Ghaleh VJ; Rezaei S; Hejazi ES; Kakavand A; Behroozaghdam M; Movafagh A; Taheriazam A; Hashemi M; Samarghandian S
    Clin Transl Oncol; 2023 May; 25(5):1167-1188. PubMed ID: 36562927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro--a quantitative study.
    Asgeirsdóttir SA; Talman EG; de Graaf IA; Kamps JA; Satchell SC; Mathieson PW; Ruiters MH; Molema G
    J Control Release; 2010 Jan; 141(2):241-51. PubMed ID: 19766679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
    Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
    Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo.
    Wei Y; Sun Y; Wei J; Qiu X; Meng F; Storm G; Zhong Z
    J Control Release; 2021 Sep; 337():521-529. PubMed ID: 34352315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.